6 million in cash now. Tax refund should be around $4 million.
So not including the options, another raise needed by end of year if shortfall isnt placed. Can extend to 1st quarter next year if it is. Or mid next year if options get in the money.
CHM needs some good data from the Cd17 trial to lift the share price well before the options timex.
7 patients recruited (6 of which we should get data from) is starting to position the company where the data needed may be delivered, if the drug works.
Financial pathway still the greatest risk. Still a vety high risk investment, but that low market cap means huge potential for upside.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)